Celsion (CLSN) receives regulatory clearance to start a Phase III study of its ThermoDox treatment for primary liver cancer in Taiwan, Hong Kong, South Korea and Canada.
The company has also applied for approval to conduct trials in the Philippines, Thailand, China and Europe
Celsion has already received FDA clearance for the study, whose primary endpoint is overall survival.
The company expects to enroll 550 patients globally at up to 100 sites. (PR)